Skip to main content
SpringerLink
Log in

Clinical outcome after percutaneous treatment of de novo coronary bifurcation lesions using first or second generation of drug-eluting stents

  • Original Paper
  • Published:
Clinical Research in Cardiology Aims and scope Submit manuscript

Abstract

Background

There is increasing evidence that various types of drug-eluting stents (DES) may differ regarding the long-term safety and efficacy, particularly in complex lesion subsets.

Aims

In a cohort of consecutive patients undergoing bifurcation stenting, we sought to compare the 1-year efficacy and safety of the first-generation paclitaxel-eluting stents (PES), the first-generation sirolimus-eluting (SES) and the second-generation everolimus- or zotarolimus-eluting stents (EES/ZES).

Methods

We treated 2197 patients (mean age 67.5 years, 75.4 % male) with provisional T-stenting for de novo coronary bifurcation lesions using PES, SES or EES/ZES. Primary endpoint (MACE) was the composite of death from any cause, myocardial infarction (MI) and target lesion revascularisation (TLR).

Results

Side branch stenting was found to be clinically indicated in 793 patients (36.1 %). The cumulative 1-year incidence of MACE was 18.8 % after PES, 13.1 % after PCI with SES and 12.2 % after EES/ZES (p = 0.003), the combined endpoint death and MI occurred in 6.6, 5.6 and 8.3 % (p = 0.253) and death in 4.3, 5.2 and 5.3 % (p = 0.581), respectively. After adjustment for co-variables the type of DES was a significant (p = 0.008) predictor of MACE [HR (95 % confidence interval) PES vs SES 1.34 (1.04–1.71), PES vs. EES/ZES 1.75 (1.19–2.57), EES/ZES vs. SES 0.762 (0.531–1.095)], but not of death (p = 0.581), death and MI (p = 0.077) or stent thrombosis (ST) (p = 0.925).

Conclusions

In de novo coronary bifurcation lesions treated with provisional T-stenting, SES and EES/ZES achieved better outcomes than PES by reducing the need for reintervention.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Dangas GD, Serruys PW, Kereiakes DJ, Hermiller J, Rizvi A, Newman W, Sudhir K, Smith RS Jr, Cao S, Theodoropoulos K, Cutlip DE, Lansky AJ, Stone GW (2013) Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv 6(9):914–922. doi:10.1016/j.jcin.2013.05.005

    Article  PubMed  Google Scholar 

  2. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A (2005) Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293(17):2126–2130. doi:10.1001/jama.293.17.2126

    Article  CAS  PubMed  Google Scholar 

  3. Ferenc M, Gick M, Kienzle RP, Bestehorn HP, Werner KD, Comberg T, Zhao M, Buettner HJ, Neumann FJ (2010) Long-term outcome of percutaneous catheter intervention for de novo coronary bifurcation lesions with drug-eluting stents or bare-metal stents. Am Heart J 159(3):454–461. doi:10.1016/j.ahj.2009.11.032

    Article  CAS  PubMed  Google Scholar 

  4. Di Mario C, Morici N, Godino C, Goktekin O, Tamburino C, Barbagallo R, Antoniucci D, Grube E, Airoldi F, Zoccai GB, Colombo A, Sangiorgi GM (2007) Predictors of restenosis after treatment of bifurcational lesions with paclitaxel eluting stents: a multicenter prospective registry of 150 consecutive patients. Catheter Cardiovasc Interv 69(3):416–424. doi:10.1002/ccd.20951

    Article  PubMed  Google Scholar 

  5. Pan M, Suarez de Lezo J, Medina A, Romero M, Delgado A, Segura J, Ojeda S, Mazuelos F, Hernandez E, Melian F, Pavlovic D, Esteban F, Herrador J (2007) Drug-eluting stents for the treatment of bifurcation lesions: a randomized comparison between paclitaxel and sirolimus stents. Am Heart J 153(1):15 e11–17. doi:10.1016/j.ahj.2006.10.017

  6. Maeng M, Holm NR, Erglis A, Kumsars I, Niemela M, Kervinen K, Jensen JS, Galloe A, Steigen TK, Wiseth R, Narbute I, Gunnes P, Mannsverk J, Meyerdierks O, Rotevatn S, Nikus K, Vikman S, Ravkilde J, James S, Aaroe J, Ylitalo A, Helqvist S, Sjogren I, Thayssen P, Virtanen K, Puhakka M, Airaksinen J, Christiansen EH, Lassen JF, Thuesen L (2013) Long-term results after simple versus complex stenting of coronary artery bifurcation lesions: nordic Bifurcation Study 5-year follow-up results. J Am Coll Cardiol 62(1):30–34. doi:10.1016/j.jacc.2013.04.015

    Article  PubMed  Google Scholar 

  7. Stone GW, Rizvi A, Sudhir K, Newman W, Applegate RJ, Cannon LA, Maddux JT, Cutlip DE, Simonton CA, Sood P, Kereiakes DJ (2011) Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. J Am Coll Cardiol 58(1):19–25. doi:10.1016/j.jacc.2011.02.022

    Article  PubMed  Google Scholar 

  8. Taniwaki M, Stefanini GG, Silber S, Richardt G, Vranckx P, Serruys PW, Buszman PE, Kelbaek H, Windecker S (2014) 4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention). J Am Coll Cardiol 63(16):1617–1625. doi:10.1016/j.jacc.2013.12.036

    Article  CAS  PubMed  Google Scholar 

  9. de Waha A, Cassese S, Park DW, Burzotta F, Byrne RA, Tada T, King LA, Park SJ, Schomig A, Kastrati A (2012) Everolimus-eluting versus sirolimus-eluting stents: an updated meta-analysis of randomized trials. Clin Res Cardiol 101(6):461–467. doi:10.1007/s00392-012-0414-8

    Article  CAS  PubMed  Google Scholar 

  10. Akin I, Hochadel M, Abdel-Wahab M, Senges J, Richardt G, Schneider S, Tebbe U, Kuck KH, Nienaber CA (2013) Clinical outcomes of different first- and second-generation drug-eluting stents in routine clinical practice: results from the prospective multicenter German DES.DE registry. Clin Res Cardiol 102(5):371–381. doi:10.1007/s00392-013-0546-5

    Article  CAS  PubMed  Google Scholar 

  11. Akin I, Nienaber CA, Richardt G, Tolg R, Hochadel M, Schneider S, Senges J, Tebbe U, Zeymer U, Sabin G, Kuck KH, Bergmann MW (2014) Risk factors for clinical events at 1-year follow-up after drug-eluting stent implantation: results from the prospective multicenter German DES.DE registry. Clin Res Cardiol 103(5):363–372. doi:10.1007/s00392-014-0662-x

    Article  CAS  PubMed  Google Scholar 

  12. Ferenc M, Gick M, Kienzle RP, Bestehorn HP, Werner KD, Comberg T, Kuebler P, Buttner HJ, Neumann FJ (2008) Randomized trial on routine vs. provisional T-stenting in the treatment of de novo coronary bifurcation lesions. Eur Heart J 29(23):2859–2867. doi:10.1093/eurheartj/ehn455

    Article  PubMed Central  PubMed  Google Scholar 

  13. Louvard Y, Thomas M, Dzavik V, Hildick-Smith D, Galassi AR, Pan M, Burzotta F, Zelizko M, Dudek D, Ludman P, Sheiban I, Lassen JF, Darremont O, Kastrati A, Ludwig J, Iakovou I, Brunel P, Lansky A, Meerkin D, Legrand V, Medina A, Lefevre T (2008) Classification of coronary artery bifurcation lesions and treatments: time for a consensus! Catheter Cardiovasc Interv 71(2):175–183. doi:10.1002/ccd.21314

    Article  PubMed  Google Scholar 

  14. Freixa X, Carpen M, Kotowycz MA, Ho KW, Krimly A, Osten MD, Overgaard CB, Horlick EM, Seidelin PH, Dzavik V (2012) Long-term outcomes after percutaneous intervention of the internal thoracic artery anastomosis: the use of drug-eluting stents is associated with a higher need of repeat revascularization. Can J Cardiol 28(4):458–463. doi:10.1016/j.cjca.2012.01.020

    Article  PubMed  Google Scholar 

  15. Stankovic G, Lefevre T, Chieffo A, Hildick-Smith D, Lassen JF, Pan M, Darremont O, Albiero R, Ferenc M, Finet G, Adriaenssens T, Koo BK, Burzotta F, Louvard Y (2013) Consensus from the 7th European Bifurcation Club meeting. EuroIntervention 9(1):36–45. doi:10.4244/EIJV9I1A7

    Article  PubMed  Google Scholar 

  16. Hahn JY, Chun WJ, Kim JH, Song YB, Oh JH, Koo BK, Rha SW, Yu CW, Park JS, Jeong JO, Choi SH, Choi JH, Jeong MH, Yoon JH, Jang Y, Tahk SJ, Kim HS, Gwon HC (2013) Predictors and outcomes of side branch occlusion after main vessel stenting in coronary bifurcation lesions: results from the COBIS II Registry (COronary BIfurcation Stenting). J Am Coll Cardiol 62(18):1654–1659. doi:10.1016/j.jacc.2013.07.041

    Article  PubMed  Google Scholar 

  17. Niemela M, Kervinen K, Erglis A, Holm NR, Maeng M, Christiansen EH, Kumsars I, Jegere S, Dombrovskis A, Gunnes P, Stavnes S, Steigen TK, Trovik T, Eskola M, Vikman S, Romppanen H, Makikallio T, Hansen KN, Thayssen P, Aberge L, Jensen LO, Hervold A, Airaksinen J, Pietila M, Frobert O, Kellerth T, Ravkilde J, Aaroe J, Jensen JS, Helqvist S, Sjogren I, James S, Miettinen H, Lassen JF, Thuesen L (2011) Randomized comparison of final kissing balloon dilatation versus no final kissing balloon dilatation in patients with coronary bifurcation lesions treated with main vessel stenting: the Nordic-Baltic Bifurcation Study III. Circulation 123(1):79–86. doi:10.1161/CIRCULATIONAHA.110.966879

    Article  PubMed  Google Scholar 

  18. Song YB, Hahn JY, Choi SH, Choi JH, Lee SH, Jeong MH, Kim HS, Seong IW, Yang JY, Rha SW, Jang Y, Yoon JH, Tahk SJ, Seung KB, Park SJ, Gwon HC (2010) Sirolimus- versus paclitaxel-eluting stents for the treatment of coronary bifurcations results: from the COBIS (Coronary Bifurcation Stenting) Registry. J Am Coll Cardiol 55(16):1743–1750. doi:10.1016/j.jacc.2010.02.008

    Article  PubMed  Google Scholar 

  19. Burzotta F, Trani C, Todaro D, Mariani L, Talarico GP, Tommasino A, Giammarinaro M, Niccoli G, Porto I, Leone AM, Mongiardo R, Mazzari MA, Schiavoni G, Crea F (2011) Prospective randomized comparison of sirolimus- or everolimus-eluting stent to treat bifurcated lesions by provisional approach. JACC Cardiovasc Interv 4(3):327–335. doi:10.1016/j.jcin.2010.12.005

    Article  PubMed  Google Scholar 

  20. Burzotta F, Trani C, Talarico GP, Tommasino A, Todaro D, Coluccia V, Pirozzolo G, Niccoli G, Leone AM, Porto I, Schiavoni G, Crea F (2013) Resolute zotarolimus-eluting stent to treat bifurcated lesions according to the provisional technique: a procedural performance comparison with sirolimus- and everolimus-eluting stents. Cardiovasc Revasc Med 14(3):122–127. doi:10.1016/j.carrev.2013.01.002

    Article  PubMed  Google Scholar 

  21. Ferenc M, Kornowski R, Belardi J, Serruys P, Silber S, Widimsky P, Windecker S, Neumann FJ (2014) Three-year outcomes of percutaneous coronary intervention with next-generation zotarolimus-eluting stents for de novo coronary bifurcation lesions. J Invasive Cardiol 26(12):630–638

    PubMed  Google Scholar 

  22. Costopoulos C, Latib A, Ferrarello S, Naganuma T, Sticchi A, Filippo F, Giannini F, Basavarajaiah S, Kawaguchi M, Naim C, Candreva A, Carlino M, Chieffo A, Montorfano M, Colombo A (2013) First- versus second-generation drug-eluting stents for the treatment of coronary bifurcations. Cardiovasc Revasc Med 14(6):311–315. doi:10.1016/j.carrev.2013.09.006

    Article  PubMed  Google Scholar 

  23. Schomig A, Dibra A, Windecker S, Mehilli J, Suarez de Lezo J, Kaiser C, Park SJ, Goy JJ, Lee JH, Di Lorenzo E, Wu J, Juni P, Pfisterer ME, Meier B, Kastrati A (2007) A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol 50(14):1373–1380. doi:10.1016/j.jacc.2007.06.047

    Article  PubMed  Google Scholar 

  24. Park KW, Kang SH, Velders MA, Shin DH, Hahn S, Lim WH, Yang HM, Lee HY, Van Boven AJ, Hofma SH, Kang HJ, Koo BK, Oh BH, Park YB, Kandzari DE, Kim HS (2013) Safety and efficacy of everolimus- versus sirolimus-eluting stents: a systematic review and meta-analysis of 11 randomized trials. Am Heart J 165(2):241–250 e244. doi: 10.1016/j.ahj.2012.08.007

  25. Cassese S, Ndrepepa G, King LA, Tada T, Fusaro M, Kastrati A (2012) Two zotarolimus-eluting stent generations: a meta-analysis of 12 randomised trials versus other limus-eluting stents and an adjusted indirect comparison. Heart 98(22):1632–1640. doi:10.1136/heartjnl-2012-302519

    Article  CAS  PubMed  Google Scholar 

  26. Ferrarello S, Costopoulos C, Latib A, Naganuma T, Sticchi A, Figini F, Basavarajaiah S, Carlino M, Chieffo A, Montorfano M, Kawaguchi M, Naim C, Giannini F, Colombo A (2013) The role of everolimus-eluting and resolute zotarolimus-eluting stents in the treatment of coronary bifurcations. J Invasive Cardiol 25(9):436–440

    PubMed  Google Scholar 

  27. Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D’Ascenzo F, Kimura T, Briguori C, Sabate M, Kim HS, De Waha A, Kedhi E, Smits PC, Kaiser C, Sardella G, Marullo A, Kirtane AJ, Leon MB, Stone GW (2012) Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 379(9824):1393–1402. doi:10.1016/S0140-6736(12)60324-9

    Article  CAS  PubMed  Google Scholar 

  28. Schulz A, Hauschild T, Kleber FX (2014) Treatment of coronary de novo bifurcation lesions with DCB only strategy. Clin Res Cardiol 103(6):451–456. doi:10.1007/s00392-014-0671-9

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology and Angiology II, University Heart Center Freiburg - Bad Krozingen, Suedring 15, 79189, Bad Krozingen, Germany

    Miroslaw Ferenc, Heinz Joachim Buettner, Michael Gick, Thomas Comberg, Juergen Rothe, Firas Khoury, Christian Valina, Aurel Toma, Piotr Kuebler, Florian Riede & Franz-Josef Neumann

Authors
  1. Miroslaw Ferenc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Heinz Joachim Buettner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Gick
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Thomas Comberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Juergen Rothe
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Firas Khoury
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Christian Valina
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Aurel Toma
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Piotr Kuebler
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Florian Riede
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Franz-Josef Neumann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Miroslaw Ferenc.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ferenc, M., Buettner, H.J., Gick, M. et al. Clinical outcome after percutaneous treatment of de novo coronary bifurcation lesions using first or second generation of drug-eluting stents. Clin Res Cardiol 105, 230–238 (2016). https://doi.org/10.1007/s00392-015-0911-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00392-015-0911-7

Keywords

Search

Navigation